Pharma giant AstraZeneca has closed the previously announced acquisition of Neogene Therapeutics, a US-based clinical-stage biotechnology company.

Neogene Therapeutics is engaged in the discovery, development, and manufacturing of next-generation T-cell receptor therapies (TCR-Ts).

AstraZeneca announced the deal to acquire the cell therapy company in November 2022 and offered a consideration of up to $320 million.

Neogene Therapeutics will now work as a fully-owned subsidiary of the pharma giant, with operations in Amsterdam and California.

Recently, AstraZeneca signed a deal to acquire CinCor Pharma, a US-based clinical-stage biopharmaceutical company, for a transaction value of about $1.8 billion.

  AstraZeneca, Neogen, Neogene Therapeutics, Pharma acquisition news, USA